OncLive Staff

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for at the upcoming ASCO Annual Meeting in Chicago, with some additional tidbits to round out the main event.

Prateek Gulhati, MD, PhD, delivers takeaways from his presentation at the 2022 Annual Oncology Clinical Practice and Research Summit and key trials in pancreatic cancer that have moved the field forward.

Manmeet Singh Ahluwalia, MD, and his wife, Harneet Kaur Walia, MD, say that they learn from each other’s experiences and share in successes.

Breast oncologists recap findings from the 2022 San Antonio Breast Cancer Symposium.

Dr Kyriakopoulos sheds light on the potential synergy between masofaniten and enzalutamide when used in combination for patients with prostate cancer.

Camidge and Farmen talk through patient advocacy, Farmen’s cancer diagnosis, and the people who rallied around Farmen during the early days of her disease.

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Dr Tripathy discusses the unique aspects of the Miami Breast Cancer Conference that make it worth returning to year after year.

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

Drs Camidge and Kelley discuss the ways Dr Kelley’s passion for research guided his early career path.

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.

Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.

Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the dynamics of helping low-income patients access cancer treatments.

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Drs Lunning and Maddocks discuss the management of MCL in the up-front setting.

Drs Camidge and Leland discuss various roles in the biotechnology field and the intricacies of starting a biotechnology company.

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.